Cite
CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
MLA
Peter Kloen, et al. CRIPTO and Its Signaling Partner GRP78 Drive the Metastatic Phenotype in Human Osteotropic Prostate Cancer. Jan. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0f4645ffd2a127d7055b2afd3b45146b&authtype=sso&custid=ns315887.
APA
Peter Kloen, Sofia Karkampouna, Rob C.M. Pelger, G J L H van Leenders, Lijkele Beimers, Zoraide Granchi, E Snaar-Jagalska, F. La Manna, Lanpeng Chen, M D Henry, Eugenio Zoni, Esther I. Verhoef, Peter C. Gray, M. Kruithof-De Julio, G. van der Pluijm, & Jonathan A. Kelber. (2017). CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
Chicago
Peter Kloen, Sofia Karkampouna, Rob C.M. Pelger, G J L H van Leenders, Lijkele Beimers, Zoraide Granchi, E Snaar-Jagalska, et al. 2017. “CRIPTO and Its Signaling Partner GRP78 Drive the Metastatic Phenotype in Human Osteotropic Prostate Cancer,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0f4645ffd2a127d7055b2afd3b45146b&authtype=sso&custid=ns315887.